



# Data Integration

# Roadmap



# Metastructures: systems approach to determine genome annotation.




# Why do we need to integrate various types of omic data?

- Get a consensus results (reduce false positive rate)
- Focusing on one type of data may miss an obvious signal




# Experimental Platforms


## Non-omics and Omics, what are they?



NMR protein structures and proteomics





DNA sequences



Transcriptome

“Non-omic”  
markers




LC-MS protein sequences and interactions

# Integration of omics data sets

| Genomics                          | Transcriptomics                                                                                                              | Proteomics                                                                                       | Metabolomics                                                                        | Protein–DNA interactions                                                                     | Protein–protein interactions                                                                                                                  | Fluxomics                                                                         | Phenomics                                                                                                                      |
|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Genomics<br>(sequence annotation) | <ul style="list-style-type: none"> <li>• ORF validation</li> <li>• Regulatory element identification<sup>74</sup></li> </ul> | <ul style="list-style-type: none"> <li>• SNP effect on protein activity or abundance</li> </ul>  | <ul style="list-style-type: none"> <li>• Enzyme annotation</li> </ul>               | <ul style="list-style-type: none"> <li>• Binding-site identification<sup>75</sup></li> </ul> | <ul style="list-style-type: none"> <li>• Functional annotation<sup>79</sup></li> </ul>                                                        | <ul style="list-style-type: none"> <li>• Functional annotation</li> </ul>         | <ul style="list-style-type: none"> <li>• Functional annotation<sup>71,103</sup></li> <li>• Biomarkers<sup>125</sup></li> </ul> |
|                                   | Transcriptomics<br>(microarray, SAGE)                                                                                        | <ul style="list-style-type: none"> <li>• Protein: transcript correlation<sup>20</sup></li> </ul> | <ul style="list-style-type: none"> <li>• Enzyme annotation<sup>109</sup></li> </ul> | <ul style="list-style-type: none"> <li>• Gene-regulatory networks<sup>76</sup></li> </ul>    | <ul style="list-style-type: none"> <li>• Functional annotation<sup>89</sup></li> <li>• Protein complex identification<sup>82</sup></li> </ul> |                                                                                   | <ul style="list-style-type: none"> <li>• Functional annotation<sup>102</sup></li> </ul>                                        |
|                                   |                                                                                                                              | Proteomics<br>(abundance, post-translational modification)                                       | <ul style="list-style-type: none"> <li>• Enzyme annotation<sup>99</sup></li> </ul>  | <ul style="list-style-type: none"> <li>• Regulatory complex identification</li> </ul>        | <ul style="list-style-type: none"> <li>• Differential complex formation</li> </ul>                                                            | <ul style="list-style-type: none"> <li>• Enzyme capacity</li> </ul>               | <ul style="list-style-type: none"> <li>• Functional annotation</li> </ul>                                                      |
|                                   |                                                                                                                              |                                                                                                  | Metabolomics<br>(metabolite abundance)                                              | <ul style="list-style-type: none"> <li>• Metabolic-transcriptional response</li> </ul>       |                                                                                                                                               | <ul style="list-style-type: none"> <li>• Metabolic pathway bottlenecks</li> </ul> | <ul style="list-style-type: none"> <li>• Metabolic flexibility</li> <li>• Metabolic engineering<sup>109</sup></li> </ul>       |
|                                   |                                                                                                                              |                                                                                                  |                                                                                     | Protein–DNA interactions<br>(ChIP–chip)                                                      | <ul style="list-style-type: none"> <li>• Signalling cascades<sup>89,102</sup></li> </ul>                                                      |                                                                                   | <ul style="list-style-type: none"> <li>• Dynamic network responses<sup>84</sup></li> </ul>                                     |
|                                   |                                                                                                                              |                                                                                                  |                                                                                     |                                                                                              | Protein–protein interactions<br>(yeast 2H, coAP–MS)                                                                                           |                                                                                   | <ul style="list-style-type: none"> <li>• Pathway identification activity<sup>89</sup></li> </ul>                               |
|                                   |                                                                                                                              |                                                                                                  |                                                                                     |                                                                                              |                                                                                                                                               | Fluxomics<br>(isotopic tracing)                                                   | <ul style="list-style-type: none"> <li>• Metabolic engineering</li> </ul>                                                      |
|                                   |                                                                                                                              |                                                                                                  |                                                                                     |                                                                                              |                                                                                                                                               |                                                                                   | Phenomics<br>(phenotype arrays, RNAi screens, synthetic lethals)                                                               |

*Nature Reviews Molecular Cell Biology*, **7**:198–210, 2006.

# Multi-omic data integration





# Challenges


1. Data Pre-processing
2. High Dimensionality
3. Multiple Testing for Marker Selection
4. Data Integration
5. Validation of the Prediction Model

# Challenge #1: Data Pre-processing

- Peak Alignment for different platforms



- Normalization among various types of data
  - Why? Remove systematic bias in the data
  - Normalization within the platform makes data comparable across samples



# Challenge # 2: High Dimensionality


# of subjects << # of variables

|            | Choles, Trig,... ... | probe set 1 ..... 22,000 | Lipid 1 ..... 2,000 | Metabolite 1 ... 3,000 | NMR 1 ..... 500 |
|------------|----------------------|--------------------------|---------------------|------------------------|-----------------|
| Animal 1   |                      |                          |                     |                        |                 |
| Animal 2   |                      |                          |                     |                        |                 |
| .          |                      |                          |                     |                        |                 |
| .          |                      |                          |                     |                        |                 |
| .          |                      |                          |                     |                        |                 |
| .          |                      |                          |                     |                        |                 |
| Animal 100 |                      |                          |                     |                        |                 |


- Genes variants: 5000 peaks
- Gene Expression (RNA-seq): 22,000 probe sets
- Protein-DNA interactions (ChIP-seq): 2, 000 peaks
- Protein interactions: 100,000,000

# Challenge #4: Data integration (How?)


## Integration Approach 1:



## Integration Approach 2:




# Example 1



Identification and quantitative comparison of genetic elements for transcription and translation initiation.

# Example 2

$\sigma$ -factor network in E. coli.



## Example 3

# **Integrative Modeling Defines the Nova Splicing-Regulatory Network and Its Combinatorial Controls**


Chaolin Zhang et al. Science 2010

# Data Integration

- More and more diverse "omics" data exist
- “It is essential to integrate various kinds of biological information and large-scale omics data sets through systematic analysis” with statistically rigorous and physically sound models
- **Bayesian Network**
- CLIP-seq (sequencing) + TF binding site (bioinformatics) + expression profile (microarray) + evolutionary signature.

# Bayesian Network

- A probabilistic graphical model that represents a set of random variables and their conditional dependencies via a directed acyclic graph.
- used to represent causal relationships.




Applications:

1. Inferring unobserved variables
2. Parameter learning


|           |      | GRASS WET |      |
|-----------|------|-----------|------|
| SPRINKLER | RAIN | T         | F    |
| F         | F    | 0.0       | 1.0  |
| F         | T    | 0.8       | 0.2  |
| T         | F    | 0.9       | 0.1  |
| T         | T    | 0.99      | 0.01 |

# Nova-regulated Alternative Splicing

- Nova proteins are a family of neuron-specific alternative splicing factors. (Ule *et al. Nature* 2006)
- The Nova protein binds to pre-message RNA at a binding site of “YCAAY” clusters.
- Nova binding to an **exonic YCAAY** cluster changed the protein complexes assembled on pre-mRNA, blocking U1 snRNP binding and exon inclusion.
- Nova binding to an **intronic YCAAY** cluster enhanced spliceosome assembly and exon inclusion.



# Data sources




- **HITS-CLIP** (CLIP-seq). Study Protein-RNA binding by crosslinking between RNA and the protein, followed by immunoprecipitation and high-throughput sequencing.
- **Genome-wide searching of YCAY motif.** Bioinformatics approach.
- **Microarray data compared WT and Nova knockout.**
- **Evolution signature.** Conserved Alternating Splicing between human and rats.

# Bayesian Model



E: Exon

U: Upstream of Intron


D: Downstream of Intron




# Estimated Conditional prob.



# Bayesian Model




# Regulation of Nova binding position




E: Exon

U: Upstream of Intron



D: Downstream of Intron




# Bayesian Model



# Splicing changes




# Bayesian Model




# Predicted Nova-regulated targets

- 13,357 annotated cassette exons


| AS type                       | AS diagram                                                                            | No. AS events |
|-------------------------------|---------------------------------------------------------------------------------------|---------------|
| Bayesian network predictions: |                                                                                       |               |
| CASS                          |    | 363           |
| TACA                          |    | 141           |
| MUTX                          |    | 37            |
| ALT5                          |   | 9             |
| ALT3                          |  | 9             |
| APA5                          |  | 13            |
| APA3                          |  | 16            |
| Bayesian network total        |                                                                                       | 588           |

# Novel Nova-regulated targets


- Besides AS from database, searched novel exons with high sequence conservations.
- Additional 76 novel exons as Nova targets




# Prediction Performance



# Reduced Bayesian Network






- Clip Data Only
- Motif Data Only




# Experimental Validation

Exon Inclusion




Exon Exclusion

# Two more Casset Exon Cases




Exon Inclusion




Exon Exclusion

# Other examples



TACA


**Exon Inclusion**



MUTX

**Exon Exclusion**

# Conservation regions



# Functions of Nova targets

- Nova regulates alternative splicing of transcripts encoding synaptic proteins.
- Go-term analysis and KEGG metabolic pathway analysis confirmed this.
- It is unclear how Nova-regulated AS might effect the interactions between those synaptic proteins.
- Protein annotations revealed that about half Nova target transcripts encoded phosphoproteins.



# GO-term enrichment of Nova targets

| GO Term                                                          | Gene count | %     | P-Value  | Fold Enrichment | Benjamini FDR |
|------------------------------------------------------------------|------------|-------|----------|-----------------|---------------|
| <i>Biological process</i>                                        |            |       |          |                 |               |
| GO:0016043~cellular component organization                       | 93         | 26.05 | 4.02E-12 | 2.02            | 6.93E-09      |
| GO:0007399~nervous system development                            | 53         | 14.85 | 1.01E-09 | 2.48            | 8.72E-07      |
| GO:0032989~cellular component morphogenesis                      | 31         | 8.68  | 2.32E-09 | 3.56            | 1.33E-06      |
| GO:0030030~cell projection organization                          | 30         | 8.40  | 3.55E-09 | 3.60            | 1.53E-06      |
| GO:0007268~synaptic transmission                                 | 22         | 6.16  | 8.39E-09 | 4.64            | 2.90E-06      |
| GO:0048667~cell morphogenesis involved in neuron differentiation | 22         | 6.16  | 1.18E-08 | 4.55            | 3.40E-06      |
| GO:0051179~localization                                          | 104        | 29.13 | 1.63E-08 | 1.66            | 4.03E-06      |
| GO:0000902~cell morphogenesis                                    | 28         | 7.84  | 1.64E-08 | 3.57            | 3.53E-06      |
| GO:0019226~transmission of nerve impulse                         | 24         | 6.72  | 2.47E-08 | 4.01            | 4.73E-06      |
| GO:0007154~cell communication                                    | 34         | 9.52  | 4.41E-08 | 2.93            | 7.60E-06      |
| <i>Cellular component</i>                                        |            |       |          |                 |               |
| GO:0045202~synapse                                               | 38         | 10.64 | 1.64E-15 | 4.85            | 5.00E-13      |
| GO:0044459~plasma membrane part                                  | 82         | 22.97 | 2.06E-15 | 2.51            | 3.16E-13      |
| GO:0042995~cell projection                                       | 47         | 13.17 | 3.24E-14 | 3.62            | 3.24E-12      |
| GO:0030054~cell junction                                         | 42         | 11.76 | 3.53E-14 | 4.00            | 2.65E-12      |
| GO:0005856~cytoskeleton                                          | 61         | 17.09 | 6.36E-12 | 2.60            | 3.81E-10      |
| GO:0005886~plasma membrane                                       | 104        | 29.13 | 6.82E-11 | 1.84            | 3.41E-09      |
| GO:0042734~presynaptic membrane                                  | 11         | 3.08  | 1.07E-09 | 14.80           | 4.61E-08      |
| GO:0016323~basolateral plasma membrane                           | 19         | 5.32  | 3.11E-09 | 5.83            | 1.17E-07      |
| GO:0044456~synapse part                                          | 23         | 6.44  | 5.65E-09 | 4.55            | 1.88E-07      |
| GO:0043005~neuron projection                                     | 25         | 7.00  | 8.93E-09 | 4.09            | 2.68E-07      |
| <i>Molecular function</i>                                        |            |       |          |                 |               |
| GO:0005515~protein binding                                       | 198        | 55.46 | 9.43E-15 | 1.49            | 4.50E-12      |
| GO:0008092~cytoskeletal protein binding                          | 35         | 9.80  | 2.57E-10 | 3.51            | 6.14E-08      |
| GO:0003779~actin binding                                         | 23         | 6.44  | 9.83E-07 | 3.40            | 1.56E-04      |
| GO:0030695~GTPase regulator activity                             | 26         | 7.28  | 1.17E-06 | 3.06            | 1.39E-04      |
| GO:0060589~nucleoside-triphosphatase regulator activity          | 26         | 7.28  | 1.61E-06 | 3.01            | 1.54E-04      |
| -----                                                            | ---        | ---   | -----    | ---             | -----         |

# Pathway enrichment of Nova targets

| KEGG pathway                               | Gene count | Fold Enrichment | Benjamini FDR | Genes                                                                                                                                      |
|--------------------------------------------|------------|-----------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| mmu04020<br>Calcium signaling pathway      | 17         | 3.5             | 0.001         | <i>Atp2b1, Atp2b2, Cacna1c, Cacna1d, Cacna1b, Cacna1g, Camk2a, Camk2g, Camk2b, Grin1, Gnas, Plcb4, Ppp3cb, Ppp3cc, Ryr2, Slc8a1, Erbb4</i> |
| mmu04720<br>Long-term potentiation         | 10         | 5.3             | 0.003         | <i>Cacna1c, Camk2a, Camk2g, Camk2b, Gria2, Grin1, Plcb4, Ppp1r12a, Ppp3cb, Ppp3cc</i>                                                      |
| mmu04514<br>Cell adhesion molecules (CAMs) | 12         | 4.1             | 0.003         | <i>Alcam, Cadm1, Cadm3, Mpz1, Neo1, Nrxa3, Nfasc, Nfasc, Ptpfr, Ptpm, Nlgn1, Nrcam, Nrxa1</i>                                              |
| mmu04520<br>Adherens junction              | 10         | 4.4             | 0.006         | <i>Actn4, Baiap2, Ctnna2, Ctnnd1, Pard3, Smad2, Smad4, Ptpfr, Ptpm, Sorbs1</i>                                                             |
| mmu04360<br>Axon guidance                  | 13         | 3.3             | 0.006         | <i>Ablim1, Cxcl12, Dcc, EphA5, Efna5, Ablim2, Ntng1, Pak3, Ppp3cb, Ppp3cc, Arhgef12, Robo2, Unc5c</i>                                      |
| mmu04912<br>GnRH signaling pathway         | 10         | 3.6             | 0.017         | <i>Cacna1c, Cacna1d, Camk2a, Camk2g, Camk2b, Gnas, Mapk8, Mapk9, Map2k4, Plcb4</i>                                                         |
| mmu04310<br>Wnt signaling pathway          | 12         | 2.8             | 0.032         | <i>Apc, Camk2a, Camk2g, Camk2b, Smad2, Smad4, Mapk8, Mapk9, Plcb4, Porcn, Ppp3cb, Ppp3cc</i>                                               |
| mmu04930<br>Type II diabetes mellitus      | 6          | 5.2             | 0.048         | <i>Cacna1c, Cacna1d, Cacna1b, Cacna1g, Mapk8, Mapk9</i>                                                                                    |
| mmu04260<br>Cardiac muscle contraction     | 7          | 4.2             | 0.049         | <i>Tpm2, Cacna1d, Cacna1c, Tpm1, Ryr2, Slc8a1, Tpm3</i>                                                                                    |
| mmu04012<br>ErbB signaling pathway         | 8          | 3.3             | 0.074         | <i>Camk2a, Camk2g, Camk2b, Mapk8, Mapk9, Map2k4, Pak3, Erbb4</i>                                                                           |
| mmu04530<br>Tight junction                 | 9          | 2.7             | 0.01          | <i>Actn4, Cask, Ctnna2, Pard3, Epb4.1, Epb4.1f1, Epb4.1f2, Epb4.1f3, Magi1</i>                                                             |

# Nova targets - phosphoproteins



# Applications of Bayesian Network

Can we apply Bayesian Network into our research?

- Next generation sequencing data, such as RNA-seq, Chip-seq etc.
- Microarray data
- Motif data, for example, TF binding sites, miRNA sequences etc.
- Genome sequence data, Ath, Maize, Rice, Soybean etc.

# Summary

- Recent technological advances present challenging and interesting biological data at molecular level.
- Statistics and multivariate analysis play an important role in understanding and extracting knowledge from these type of data.
- Integrative analysis is even more challenging and we presented some solutions to these challenges. There is plenty of room for improvement.